<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:video="http://www.google.com/schemas/sitemap-video/1.1">

  <url>
    <loc>https://www.padcevhcp.com/video-resources</loc>

    <video:video>
      <video:title>Treating a cisplatin-eligible patient</video:title>
      <video:thumbnail_loc>https://www.padcevhcp.com/Content/hcp/images/treating-cisplatin-eligible-thumb.png</video:thumbnail_loc>
      <video:description>Dr. Pedro Barata considers selection of a 1L la/mUC treatment option in a shifting landscape, with a discussion of Patricia,* a hypothetical cisplatin-eligible patient.</video:description>
      <video:player_loc>https://streams.bitmovin.com/d2ipvq2rjvh1brijq5pg/manifest.m3u8</video:player_loc>
      <video:live>no</video:live>
    </video:video>

    <video:video>
      <video:title>Treating a cisplatin-ineligible patient</video:title>
      <video:thumbnail_loc>https://www.padcevhcp.com/Content/hcp/images/treating-cisplatin-ineligible-thumb.png</video:thumbnail_loc>
      <video:description>Dr. Pedro Barata explores treating cisplatin-ineligible patients with the hypothetical patient case of Anthony,* and the need for appropriate monitoring of preexisting peripheral neuropathy.</video:description>
      <video:player_loc>https://streams.bitmovin.com/d2iq91pbpc5jk8pni8j0/manifest.m3u8</video:player_loc>
      <video:live>no</video:live>
    </video:video>

    <video:video>
      <video:title>Addressing skin reactions</video:title>
      <video:thumbnail_loc>https://www.padcevhcp.com/Content/hcp/images/addressing-skin-reaction-thumb.png</video:thumbnail_loc>
      <video:description>Dr. Pedro Barata discusses skin reactions that may arise during treatment with a conversation about Rebecca,* a hypothetical cisplatin-eligible patient.</video:description>
      <video:player_loc>https://streams.bitmovin.com/d2iq951bpc5jk8pni8jg/manifest.m3u8</video:player_loc>
      <video:live>no</video:live>
    </video:video>

    <video:video>
      <video:title>Monitoring for hyperglycemic adverse reactions</video:title>
      <video:thumbnail_loc>https://www.padcevhcp.com/Content/hcp/images/monitoring-hyperglycemic-reactions-thumb.png</video:thumbnail_loc>
      <video:description>Dr. Pedro Barata reviews hyperglycemic reactions that may occur during treatment, as with Carl,* a hypothetical cisplatin-eligible patient.</video:description>
      <video:player_loc>https://streams.bitmovin.com/d2iq7birjvh1brijq5q0/manifest.m3u8</video:player_loc>
      <video:live>no</video:live>
    </video:video>

    <video:video>
      <video:title>Helping manage adverse reactions and supporting patients</video:title>
      <video:thumbnail_loc>https://www.padcevhcp.com/Content/hcp/images/manage-adverse-reactions-thumb.png</video:thumbnail_loc>
      <video:description>Advanced Practice Nurse Dawn Conway shares her experience treating la/mUC, managing adverse reactions, and building strong patient relationships to support treatment.</video:description>
      <video:player_loc>https://streams.bitmovin.com/d2iqk0arjvh1brijq5r0/manifest.m3u8</video:player_loc>
      <video:live>no</video:live>
    </video:video>

  </url>

</urlset>